Question normal

I'm sure you're well aware of activist investors like Bill Ackman entering the pharma sector and significantly impacting health care M&A. It seems that a lot of the effects of these transactions significantly reduce investment on research and development, yet have thrived. Do you think that this trend is sustainable, and what do effects do you project this trend having on the future of pharmaceutical innovation?

Again, thank you so much for taking the time to be here.

Ramin Lalezari